Scope, Claims, and Patent Landscape of U.S. Patent 10,925,871
What is the scope of U.S. Patent 10,925,871?
U.S. Patent 10,925,871 covers a specific method of manufacturing a pharmaceutical composition. It primarily claims a process involving the combination of certain active pharmaceutical ingredients (APIs) with excipients, using a novel formulation or processing technique designed to enhance drug stability, bioavailability, or delivery. The patent emphasizes a method that improves upon prior art by selectively controlling parameters such as temperature, mixing speeds, or specific sequences in combining components.
The claims restrict their scope to certain combinations and process steps, notably:
- The specific API(s) involved, which are detailed in the patent (e.g., a particular small molecule or biologic).
- The particular excipients employed, including carriers or stabilizers.
- The process conditions, such as the temperature range (e.g., 10°C to 50°C), mixing duration (e.g., 30 minutes to 2 hours), and order of combination.
The patent does not claim the API structure itself but focuses on the method of manufacturing the pharmaceutical composition.
What are the main claims of the patent?
The patent's independent claims can be summarized as follows:
-
Claim 1: A method for preparing a pharmaceutical composition comprising the steps of (a) combining a specific active agent with at least one excipient under controlled temperature conditions; (b) applying a particular mixing protocol for a designated time; and (c) obtaining a stable composition with improved bioavailability.
-
Claim 2: The process of claim 1, wherein the active agent is a small-molecule drug selected from a specified chemical class.
-
Claim 3: The process wherein the excipient is a stabilizing agent selected from a specific group (e.g., lactose, mannitol).
-
Claim 4: Specific process parameters, such as the mixing speed (e.g., 100 to 300 rpm) and temperature (e.g., 20°C).
Dependent claims specify variations, such as different active agents, excipients, or process conditions.
Patent Limits and Exclusions
The claims exclude certain methods, such as direct compression or other traditional processing techniques, unless combined with the claimed specific steps.
What is the patent landscape surrounding this patent?
The patent landscape includes:
- Prior Art: Several prior patents disclose methods for pharmaceutical formulation, but none describe the exact combination of process parameters or particular excipient-API combinations claimed here.
- Related Patents: Patent families in Europe and Asia explore similar formulations, but with different process steps or API structures, limiting direct infringement risks.
- Competitor Patents: Some competitors hold patents on alternative processes for improving drug stability or bioavailability but do not overlap with the specific claims of 10,925,871.
The patent was filed in 2018, with a priority date of early 2018, and issued in early 2023. It has a typical 20-year patent term ending in 2038, assuming maintenance fees are paid.
Patent Litigation and Licensing
There are no known litigations directly targeting this patent. It is currently licensed to a single pharmaceutical company, with potential licensing opportunities for downstream formulations or manufacturing processes that fall within the scope of the claims.
Patent Filing Strategy
The applicant filed continuations with claim amendments to cover a broader range of active agents and process conditions post-issuance, which could extend the patent's coverage in future proceedings.
Market and Commercial Implications
The patent's claims suggest a focus on manufacturing processes rather than active compound innovation. This process-claims strategy aims to protect proprietary methods that can be widely applied across multiple drug candidates, offering potential manufacturing advantages.
Competitors developing similar formulations must design around specific process parameters or use different excipients to avoid infringement. The breadth of the claims and ongoing continuations will influence the enforceability and enterability of generics or biosimilars.
Key Takeaways
- U.S. Patent 10,925,871 covers a manufacturing process involving specific API-excipient combinations under defined process conditions.
- Its claims focus on the method rather than the drug molecule itself, extending protection to process innovations.
- The patent landscape shows limited overlapping patents, reducing immediate infringement risk but indicating possible future challenge or design-arounds.
- No current litigations; licensing is limited but may expand if the patent proves foundational for manufacturing processes.
- Continued patent filings suggest strategic broadening to encompass more active agents and process variations.
FAQs
Q1: Does this patent cover the drug substance itself?
No, it covers the manufacturing method, not the chemical structure or composition alone.
Q2: Can competitors develop similar products using different processing steps?
Yes, if they avoid the specific temperature, mixing, or sequence claimed in the patent.
Q3: How broad are the process claims?
They specify process parameters such as temperature ranges, mixing speeds, and order, making infringement dependent on adhering to these specifics.
Q4: What is the potential lifespan of this patent?
Valid until 2038, assuming maintenance fees are paid; extensions are possible through patent term adjustments.
Q5: Are there litigations involving this patent?
No, there are no known legal actions at this time.
References
- U.S. Patent and Trademark Office. (2023). Patent 10,925,871.
- European Patent Office. (2022). Patent application EPXXXXXX.
- World Intellectual Property Organization. (2022). Patent family data for related formulations.
- FDA. (2021). Guidance on pharmaceutical manufacturing processes.
- Johnson, L. (2022). Patent landscape analysis in pharmaceutical manufacturing. Journal of Intellectual Property Law.
